Therapeutic and preventive treatment on outcomes of hepatitis B virus induced chronic liver disease with a cost-effectiveness analysis.

Hepatitis B virus (HBV) is one of the major micro-pathogens in the progression of chronic liver infections worldwide. Despite a vaccine and anti-virus drugs used in the management of HBV infection, the prognosis and outcomes of this chronic infection remain complex and the infection can easily recur. Several parameters such as host age, viral mutations and genotypes, regional distributions, etc. have an effect on the outcome of hepatitis B infection following preventive measures and therapy around viral life cycle in the clinic. In addition, the economic status in different regions and groups of patients also affect disease progression. A cost-effectiveness analysis is considered to play a critical role in the management of chronic HBV infection. This mini-review investigates the above-mentioned aspects and provides a perspective viewpoint for the management of HBV infection in the future.